A sedative and hypnotic that has been used in the short-term management of INSOMNIA. Its use has been superseded by other drugs.
Medical procedure involving the emptying of contents in the stomach through the use of a tube inserted through the nose or mouth. It is performed to remove poisons or relieve pressure due to intestinal blockages or during surgery.
Clinical signs and symptoms caused by nervous system injury or dysfunction.
A hypnotic and sedative. Its use has been largely superseded by other drugs.

Rate of decrease in serum ethchlorvynol concentrations after extreme overdosage-a case study. (1/11)

Ethchlorvynol is a commonly abused sedative hypnotic. I report here a seven-day study of serum ethchlorvynol concentrations in a patient who had received an extreme overdose. These concentrations were correlated with the patient's response to stimuli. Serum ethchlorvynol concentrations were logarithmically related to time, a fact that can be useful in predicting when a patient's serum ethchlorvynol concentration will return to a therapeutic concentration. In this case the decrease was about 35% per 24h.  (+info)

A CLINICAL EVALUATION OF FOUR HYPNOTIC AGENTS, USING A LATIN-SQUARE DESIGN. (2/11)

A double-blind study with a Latin-square design was undertaken on 25 elderly patients, using a placebo and four hypnotic drugs: ethchlorvynol 500 mg., glutethimide 500 mg., chloral hydrate 500 mg., and secobarbital sodium 100 mg. The trial lasted for five weeks. The drugs were all effective compared with the placebo, differences in sleeping time being statistically significant. Differences between these four drugs were not statistically significant. Sleep was induced soonest by secobarbital and ethchlorvynol. Ethchlorvynol and glutethimide had a relatively somewhat longer period of activity than the others. Glutethimide produced most side effects, especially morning drowsiness. Ethchlorvynol and chloral hydrate produced relatively few cases of drowsiness.  (+info)

Bronchoalveolar lavage in an animal model of acute lung injury. Relationship between enhanced membrane permeability and transvascular neutrophil flux. (3/11)

Results of studies utilizing bronchoalveolar lavage (BAL) have led workers to propose that the neutrophil serves as the pivotal cellular element responsible for promoting enhanced alveolar capillary membrane (ACM) permeability in certain forms of acute lung injury. The authors performed BAL on anesthetized, intubated, instrumented sheep before and after the administration of 15 mg/kg ethchlorvynol, a known pulmonary edemagenic agent. Bronchoalveolar lavage fluid (BALF) protein content increased from 0.62 +/- 0.05 to 1.5 +/- 0.15 mg/ml, and the percentage of neutrophils recovered from 2% +/- 1% at baseline to 35% +/- 7% (P less than 0.01) 60 minutes after infusion of ethchlorvynol. After ethchlorvynol infusion into neutropenic sheep (less than 500 cells/microliter), BALF protein content increased from 0.35 +/- 0.08 to 1.5 +/- 0.69 mg/ml (P less than 0.01) with no increase in BALF neutrophil count. In 3 non-neutropenic sheep BAL was performed at 15 and 30 minutes after ethchlorvynol infusion. BALF protein content increased significantly within 15 minutes, whereas the percentage of neutrophils did not change. These findings suggest coexistent ACM injury as reflected by increases in BALF protein content and increased number of neutrophils in BALF does not necessarily imply a cause-and-effect relationship in certain forms of acute lung injury.  (+info)

Inhibition of endothelial cell retraction by ATP depletion. (4/11)

To determine the relationship among endothelial cell (EC) retraction, cell adenosine triphosphate (ATP), and the status of cellular actin, ATP levels, F-actin content, and cytochemical redistribution in bovine pulmonary artery endothelial cells were assessed. EC monolayers 7 days after confluence were exposed to ethchlorvynol (ECV), histamine, or cytochalasin B (cyto B) for time intervals from 5-90 minutes. All 3 agents resulted in endothelial cell retraction without significant effect on cellular ATP content. Sixty-minute incubation of monolayers in glucose-free media containing antimycin A and 2-deoxyglucose depleted cellular ATP to less than 10% of control levels. ATP depleted monolayers failed to retract when incubated with ECV, histamine, or cyto B. ATP depletion resulted in loss of the prominent EC margins but only a rare gap between adjacent cells. When ATP levels were allowed to recover, the ability of EC monolayers to retract was restored. Actin filaments in control monolayers localized to a dense peripheral band of actin, a paranuclear complex, and bundles of microfilaments orientated parallel to the long axis of the cell. ECV induced complete loss of the dense peripheral band and other changes in the actin disposition. Monolayers exposed to histamine showed a retraction of the dense peripheral band of actin to a subcortical position. Cyto B caused loss of the dense peripheral band and the longitudinal microfilament bundles. Monolayers depleted of ATP lost their dense peripheral band and exhibited a disorganized, tangled web of microfilaments. Neither histamine nor ECV modified the actin distribution in ATP-depleted monolayers, whereas exposure to cyto B resulted in substantial change in actin with formation of a rim inside the cell membrane and considerable loss of actin filaments. ECV or histamine induced a small reduction in F-actin content while cyto B resulted in a 50% decline in 15 minutes. ATP depletion resulted in a 19% decrease in F-actin, with no further reduction on subsequent exposure to histamine or ECV. Cyto B treatment of ATP-depleted monolayers caused a drop in F-actin content equivalent to that observed in cells with normal ATP levels. These studies indicate that ATP is essential for changes in actin filament distribution and endothelial cell retraction produced by ECV, histamine or cyto B, and make it unlikely that any of these agents acts simply by depolymerization of actin filaments or modification of the dense peripheral band, although disruption of the dense peripheral band may facilitate retraction in the presence of adequate levels of cell ATP.  (+info)

Acute urinary retention precipitated by ethchlorvynol overdose. (5/11)

A 75-year-old woman developed acute urinary retention after ingestion of 20 100 mg ethchlorvynol tablets in a suicide attempt. To the authors' knowledge acute bladder dysfunction has not been previously ascribed to ethchlorvynol, but has been described often with therapy with various psychotropic medications. The mechanism of such bladder dysfunction may be direct action on bladder muscle, or parasympathetic cholinergic blockade, but has not been clarified. The risk of acute bladder dysfunction and the possibility of underlying bladder disorder must be considered in all patients receiving sedative-hypnotic drugs, particularly the elderly.  (+info)

The effect of ethchlorvynol on cultured endothelial cells. A model for the study of the mechanism of increased vascular permeability. (6/11)

Ethchlorvynol (ECV), an agent which produces reversible pulmonary edema, was studied for its effects on cultured bovine pulmonary artery endothelial cell (BPAE) and human umbilical vein endothelial cell (HUVE) monolayers. Endothelial cell monolayers 6 days post-confluent were treated with 1 mg/ml ECV for time intervals of from 5 minutes to 15 hours. ECV treatment caused a mild endothelial cell retraction evident at 10 minutes which increased in severity with increasing duration of exposure to ECV. Retraction of endothelial cells resulted in the formation of irregularly delineated gaps between cells, which remained attached to one another by slender filamentous processes. Despite the severity of the endothelial cell lesion, no cell lysis or cell detachment from the substratum occurred. Furthermore, removal of ECV from cell cultures resulted in the reversal of the endothelial cell lesion. Cytochemical distribution of actin microfilaments in control monolayers localized to a dense peripheral band of actin filaments and to a set of interconnected central microfilaments oriented in general parallel to the long axis of the cell. Endothelial cells treated with ECV for as little as 10 minutes showed a loss of F-actin from the dense peripheral band of microfilaments progressing until the dense peripheral band was entirely lost after 4 hours' exposure to ECV. By 4 hours central microfilaments had reorganized into a prominent series of microfilament bundles aligned parallel to each other and to the long axis of the cell. For investigation of a possible loss of attachment sites of actin filaments as the basis for the lesion, the localization of vinculin was examined in control and ECV-treated BPAE monolayers. After 2 hours' exposure to ECV, vinculin localization within monolayers was affected little, if at all. No effects of ECV on intermediate filaments were observed either. It is proposed that the dense peripheral band of actin bundles is important in maintaining well-spread endothelial cells in monolayers and that ECV acts to destroy the integrity of this structure. It is further proposed that a reaction of endothelial cells to ECV in vivo analogous to that seen in tissue culture accounts for the production of pulmonary edema by creating gaps between cells.  (+info)

Ethchlorvynol (Placidyl) intoxication and its treatment by hemodialysis. (7/11)

Twenty hours after ingesting 15-25 g. of ethchlorvynol, a 37-year-old woman was admitted comatose and in shock. The blood level of ethchlorvynol was 21.6 mg. % (method of Wallace). Supportive measures were instituted and hemodialysis, carried out for 10 hours, removed 5.49 g. of the drug. The post-dialysis blood level was 9.05 mg. % and the rate of dialysance was 50.5 ml./min. Only 0.6 g. of the substance was recovered from the urine over the same period.Although dialysis removed significant amounts of the drug and sustained life, the patient remained comatose for five days before withdrawal symptoms and seizures developed.  (+info)

Preliminary report on the effects of totigestational exposure to ethchlorvynol. (8/11)

Ethchlorvynol, a sedative-hypnotic drug used clinically since 1955, has recently been the subject of renewed interest primarily because of its chemical relationship to vinyl chloride. In our totigestational studies, sperm-positive female rats were given a daily dose of ethchlorvynol dissolved in olive oil for 21 consecutive days. The dams were allowed to deliver and their offspring were observed for alterations in development by monitoring a number of gross behavioral, histological and biochemical parameters at newborn, weanling, puberty, adult and geriatric stages. Gross development appeared normal at time of weaning: however, offspring of treated dams showed increased behavioral activity in addition to alterations in a number of clinical chemistry parameters. The dose-response seen with most of the parameters suggests that the changes are drug related. However, the clinical pathological significance has not been ascertained.  (+info)

Ethchlorvynol is a sedative-hypnotic drug that was previously used for the treatment of insomnia and anxiety disorders. It belongs to the class of drugs known as carbamates, which act on the central nervous system to produce a calming effect. Ethchlorvynol has been largely discontinued due to its potential for abuse and dependence, as well as its association with serious side effects such as respiratory depression and death. It is no longer available for medical use in many countries, including the United States.

Gastric lavage, also known as stomach pumping, is a medical procedure where the stomach's contents are emptied using a tube that is inserted through the mouth or nose and into the stomach. The tube is then connected to suction, which helps remove the stomach contents. This procedure is often used in emergency situations to treat poisonings or overdoses by removing the toxic substance before it gets absorbed into the bloodstream. It can also be used to empty the stomach before certain surgeries or procedures.

Neurologic manifestations refer to the signs and symptoms that occur due to a disturbance or disease of the nervous system, which includes the brain, spinal cord, nerves, and muscles. These manifestations can vary widely depending on the specific location and nature of the underlying problem. They may include motor (movement-related) symptoms such as weakness, paralysis, tremors, or difficulty with coordination; sensory symptoms such as numbness, tingling, or pain; cognitive or behavioral changes; seizures; and autonomic symptoms such as changes in blood pressure, heart rate, or sweating. Neurologic manifestations can be caused by a wide range of conditions, including infections, injuries, degenerative diseases, strokes, tumors, and autoimmune disorders.

Glutethimide is a sedative-hypnotic drug that was previously used for the treatment of insomnia and anxiety disorders. It belongs to the class of drugs known as non-barbiturate hypnotics. Glutethimide works by depressing the central nervous system (CNS), producing a calming effect on the brain.

Due to its potential for abuse, addiction, and its narrow therapeutic index, glutethimide is no longer commonly used in clinical practice. It has been replaced by safer and more effective sleep aids with fewer side effects and lower potential for misuse.

It's important to note that the use of glutethimide should be under the strict supervision of a healthcare professional, and it should only be taken as prescribed. Misuse or overuse of this medication can lead to serious health consequences, including respiratory depression, coma, and even death.

... is a GABA-ergic sedative and hypnotic/soporific medication first developed by Pfizer in the 1950s. In the United ... Ethchlorvynol was used to treat insomnia, but prescriptions for the drug had fallen significantly by 1990, as other hypnotics ... Ethchlorvynol is a member of the class of sedative-hypnotic carbinols, which includes methylparafynol and tert-amyl alcohol. It ... Ethchlorvynol is not compatible with intravenous injection and serious injury (including the loss of limbs due to vascular ...
Pyrithyldione Piperidione Bemegride Thalidomide Glutethimide Phenglutarimide Ethchlorvynol Anvisa (2023-03-31). "RDC Nº 784 - ...
... chloral hydrate diethyl ether ethchlorvynol (Placidyl; "jelly-bellies") gamma-butyrolactone (GBL, a prodrug to GHB) gamma- ...
His victims were typically plied with alcohol and sedatives such as ethchlorvynol before their restraint and murder. Several ...
2-Methyl-1-butanol 2-Methyl-2-pentanol 3-Methyl-3-pentanol Alcohols Amyl alcohol Diethylpropanediol Pentanols Ethchlorvynol ...
1,6-Dioxecane-2,7-dione 2-Methyl-2-butanol 2-Methyl-2-pentanol 3-Methyl-3-pentanol Clocental Ethchlorvynol Methylpentynol ...
... clobazam clonazepam clorazepate clotiazepam cloxazolam cyclobarbital delorazepam diazepam estazolam ethchlorvynol ethinamate ...
... ethchlorvynol gamma-hydroxybutyric acid (GHB) methyprylon Stimulants: amfepramone aminorex benzphetamine etilamfetamine ...
... and any salt thereof Ethchlorvynol (ethyl-2-chlorovinyl ethynyl carbinol) Ethinamate (1-ethynylcyclohexanol carbamate) Mazindol ...
... methylpentynol and ethchlorvynol. Ro15-4513 is structurally related to the benzodiazepine antidote flumazenil. The main ...
After Eyler had plied Bibbs with vodka and ethchlorvynol, he drove him to the abandoned farmhouse in Lake Village where he had ...
... chloride/dichloromethane Clotiazepam Cloxazolam Delorazepam Diazepam Diclazepam Esketamine Estazolam Eszopiclone Ethchlorvynol ...
... ethchlorvynol, and chloralodol. Unlike primary alcohols like ethanol, these tertiary alcohols cannot be oxidized into aldehyde ...
Ethchlorvynol (Placidyl) GHB Glutethimide (Doriden) Methaqualone Ketamine (T41.2) Among stimulants (F14-F15) Cocaine overdose ( ...
... ethchlorvynol, methyprylon and chlordiazepoxide were drugs whose usefulness "can hardly be questioned." However, Essig labeled ...
... ethchlorvynol MeSH D02.033.260.350 - ethylene chlorohydrin MeSH D02.033.375.270 - ethamoxytriphetol MeSH D02.033.375.291 - ...
Amobarbital Amphetamine Barbital Cyclobarbital Dexamphetamine Ethchlorvynol Glutethimide Ketamine Meprobamate Methamphetamine ...
3-propanediol 2-Methyl-2-butanol 2-Methyl-2-pentanol 3-Methyl-3-pentanol 3-Hydroxybutanal Ethchlorvynol Phenaglycodol Berger FM ...
... presumably Ethchlorvynol) Ethinamate Flunitrazepam (moved up from Schedule 4 by 1993 Regulations) 4-Hydroxybutanoic acid (added ...
Ethchlorvynol (ethyl-2-chlorovinyl-ethinyicabinol) Lorazepam (7-Chloro-5(o-chlorophenyl)-1,3-dihydro-3-hydroxy-2H-1, 4- ...
... is structurally and somewhat pharmacodynamically similar to ethchlorvynol, a pharmaceutical developed during ...
Clocental Ethchlorvynol Anvisa (2023-03-31). "RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e ...
N05CM03 Bromisoval N05CM04 Carbromal N05CM05 Scopolamine N05CM06 Propiomazine N05CM07 Triclofos N05CM08 Ethchlorvynol N05CM09 ...
... ethchlorvynol (INN) ethenzamide (INN) ethinamate (INN) ethinylestradiol (INN) ethiodized oil (131 I) (INN) Ethiodol (Savage ...
The fact that the simpler clandestine synthesis of other extinct pharmaceutical depressants like ethchlorvynol, methyprylon, or ...
Ethchlorvynol is a GABA-ergic sedative and hypnotic/soporific medication first developed by Pfizer in the 1950s. In the United ... Ethchlorvynol was used to treat insomnia, but prescriptions for the drug had fallen significantly by 1990, as other hypnotics ... Ethchlorvynol is a member of the class of sedative-hypnotic carbinols, which includes methylparafynol and tert-amyl alcohol. It ... Ethchlorvynol is not compatible with intravenous injection and serious injury (including the loss of limbs due to vascular ...
"Ethchlorvynol" is a descriptor in the National Library of Medicines controlled vocabulary thesaurus, MeSH (Medical Subject ... This graph shows the total number of publications written about "Ethchlorvynol" by people in this website by year, and whether ... Pleural effusions associated with ethchlorvynol lung injury result from visceral pleural leak. Am Rev Respir Dis. 1989 Sep; 140 ... Below are the most recent publications written about "Ethchlorvynol" by people in Profiles. ...
Ethchlorvynol crosses the placenta.. Uses and Administration. Ethchlorvynol is a hypnotic and sedative with some anticonvulsant ... The effect of ethchlorvynol may be enhanced by alcohol, barbiturates, and other CNS depressants. Ethchlorvynol has been ... Synonyms: E-Ethchlorvynol; β-Chlorovinyl Ethyl Ethynyl Carbinol; Etclorvinol; Ethchlorvynol; Etkloorivinoli; Etklorvinol ... Ethchlorvynol should be used with caution in patients with hepatic or renal impairment or with depression, in patients with ...
Ethchlorvynol: Pharmacologic management of acute abstinence syndromes - withdrawal symptoms. Health and Medicine Reference ... Ethchlorvynol. Ethchlorvynol is a sedative and hypnotic drug. It has been used to treat insomnia, but has been largely ... Ethchlorvynol. Ethosuximide. Ethotoin. Etiracetam. Etodolac. Etopophos. Etoposide. Etorphine. Evista. Exelon. Exemestane. Hexal ... Ethchlorvynol is a member of the class of sedative-hypnotic tertiary carbinols such as methylparafynol. It is not a barbituric ...
Neonatal withdrawal syndrome, generically termed neonatal abstinence syndrome (NAS), is a complex disorder. It is defined as a constellation of behavioral and physiological signs and symptoms that are remarkably similar despite marked differences in the properties of the causative agent.
Article 5.. North Carolina Controlled Substances Act. 90-86. Title of Article.. This Article shall be known and may be cited as the North Carolina Controlled Substances Act. (1971, c. 919, s. 1.). 90-87. Definitions.. As used in this Article:. (1) Administer means the direct application of a controlled substance, whether by injection, inhalation, ingestion, or any other means to the body of a patient or research subject by:. a. A practitioner (or, in his presence, by his authorized agent), or. b. The patient or research subject at the direction and in the presence of the practitioner.. (2) Agent means an authorized person who acts on behalf of or at the direction of a manufacturer, distributor, or dispenser but does not include a common or contract carrier, public warehouseman, or employee thereof.. (3) Bureau means the Bureau of Narcotics and Dangerous Drugs, United States Department of Justice or its successor agency.. (3a) Commission means the Commission for Mental Health, ...
Detailed drug Information for Carbihist. Includes common brand names, drug descriptions, warnings, side effects and dosing information.
Detailed drug Information for Xolox. Includes common brand names, drug descriptions, warnings, side effects and dosing information.
This medicine may cause some people to be agitated, irritable, or display other abnormal behaviors, such as feeling sad or hopeless, getting upset easily, or feeling nervous, restless, or hostile. It may also cause some people to have suicidal thoughts and tendencies or to become more depressed. If you or your caregiver notice any of these side effects, tell your doctor right away. This medicine may cause respiratory depression, a serious breathing problem that can be life-threatening, when used together with narcotic pain medicines. Check with your doctor right away if you have pale or blue lips, fingernails, or skin, difficult or troubled breathing, or irregular, fast or slow, or shallow breathing. Check with your doctor right away if you have a fever, rash, swollen, painful, or tender lymph glands in the neck, armpit, or groin, unusual bleeding or bruising, or yellow eyes or skin. These may be symptoms of a serious and life-threatening allergic reaction called drug reaction with eosinophilia ...
s) Ethchlorvynol.. (t) Ethinamate.. (u) Ethyl loflazepate.. (v) Fencamfamin.. 1(w) Fenfluramine. ...
Red Pills : Ethchlorvynol? Secobarbital? Chloral Hydrate?. Would Be Nice for a Short Term Relief. Easygo. Pharms - ...
Ethchlorvynol. 113-18-8. 16.. Ethinamate. 126-52-3. 17.. Ethyl loflazepate. 29177-84-2. ...
4) Ethchlorvynol. (5) Ethinamate. (6) Methohexital. (7) Meprobamate. (8) Methylphenobarbital. (9) Paraldehyde. (10) ...
Alcohol & their carbamate derivatives: Meprobomate, Ethchlorvynol.. Aldehyde & their derivatives: Triclofos sodium, Paraldehyde ...
Transient delirium has been reported in patients who were treated with one gram of ethchlorvynol and 75 to 150 mg of ... Caution is advised if patients receive large doses of ethchlorvynol concurrently. ...
Controlled Ingredient: ethchlorvynol, 750 mg. Travel back to the DRCNet Response to the DEA Home Page ...
Other non-barbiturate sedatives or hypnotics-Includes chloral hydrate, ethchlorvynol, glutethimide, methaqualone, and other non ...
Central nervous system depressants (e.g., barbiturates, opioids, glutethimide, chloral hydrate, methaqualone, ethchlorvynol, ...
Ethchlorvynol (Placidyl), Methyprylon (Nodudar)] have limited availability and are rarely used due to limited efficacy, ...
ethchlorvynol. December 9, 2018 * reevaluation. November 16, 2018 * uncomprehending. November 21, 2018 ...
ETHCHLORVYNOL 52105 ETHER 52110 ETHINAMATE 52115 ETHIONAMIDE 52120 ETHOHEPTAZINE 52125 ETHOPROPAZINE 52130 ETHOSUXIMIDE 52135 ...
So for every Tom Waits ("Chocolate Jesus") and Friends of Dean Martinez ("Ethchlorvynol") there were duds by Marky Ramone and ...
... skelaxin pictures sparrowlike usuals underpin nonsolubly cheap carbidopa levodopa entacapone generic a canada any ethchlorvynol ...
R-134a began being phased out from use in the European Union, starting in the mid 2010s, by a directive of 2006, recommending the replacement of gases in air conditioning systems with a GWP above 100. [13] 1,1,1,2-tetrafluoroethane is subject to use restrictions in the US and other countries as well. The Society of Automotive Engineers (SAE) has proposed that it be best replaced by a new fluorochemical refrigerant HFO-1234yf (CF3CF=CH2) in automobile air-conditioning systems.[14] By model year 2021, newly manufactured light-duty vehicles in the United States will no longer use R-134a.[3] California may also prohibit the sale of canned R-134a to individuals to avoid non-professional recharge of air conditioners.[15] A ban had been in place in Wisconsin since October 1994 under ATCP 136 prohibiting sales of container sizes holding less than 15 lbs of 1,1,1,2-tetrafluoroethane, but this restriction applied only when the chemical was intended to be a refrigerant. However, the ban was lifted in ...
Paraldehyde is the cyclic trimer of acetaldehyde molecules.[2] Formally, it is a derivative of 1,3,5-trioxane, with a methyl group substituted for a hydrogen atom at each carbon. The corresponding tetramer is metaldehyde. A colourless liquid, it is sparingly soluble in water and highly soluble in ethanol. Paraldehyde slowly oxidizes in air, turning brown and producing an odour of acetic acid. It attacks most plastics and rubbers and should be kept in glass bottles. Paraldehyde was first observed in 1835 by the German chemist Justus Liebig; its empirical formula was determined in 1838 by Liebigs student Hermann Fehling.[3][4] The German chemist Valentin Hermann Weidenbusch (1821-1893), another of Liebigs students, synthesized paraldehyde in 1848 by treating acetaldehyde with acid (either sulfuric or nitric acid) and cooling to 0°C. He found it quite remarkable that when paraldehyde was heated with a trace of the same acid, the reaction went the other way, recreating acetaldehyde.[5][6] ...
DETERMINATION OF ETHCHLORVYNOL BY HIGH-PRESSURE LIQUID CHROMATOGRAPHY.NEEDHAM LL; KOCHHAR MM.1975; J. CHROMATOGR.; NETHERL.; DA ...

No FAQ available that match "ethchlorvynol"

No images available that match "ethchlorvynol"